Mereo BioPharma (MREO) Profit After Tax (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Profit After Tax data on file, last reported at -$8.5 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 34.3% year-over-year to -$8.5 million in Q1 2026; TTM through Mar 2026 was -$39.7 million, a 15.82% increase from a year earlier, with the FY2025 full-year figure at -$41.9 million, up 3.18% from the prior year.
• Profit After Tax for Q1 2026 stood at -$8.5 million, down from -$7.4 million in the prior quarter.
• Over the last five years, Profit After Tax for MREO reached as high as -$1.8 million in Q2 2023 and fell as low as -$15.0 million in Q3 2024.
• Historically, Profit After Tax has averaged -$9.3 million across 4 years, with a median of -$9.0 million in 2024.
• Across the five-year window, Profit After Tax tumbled 599.89% in 2024 and jumped 38.06% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$5.0 million in 2023, then sank by 40.75% to -$7.0 million in 2024, then declined by 4.33% to -$7.4 million in 2025, then decreased by 15.18% to -$8.5 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$8.5 million in Q1 2026, -$7.4 million in Q4 2025, and -$9.3 million in Q3 2025.